Published in Blood Weekly, July 1st, 2004
According to a study from the United States, "The antimicrobial impregnated central venous catheter (CVC) has been the most intensively studied technology for the prevention of CVC-related bloodstream infections (BSIs) over the past 30 years."
"Although more than a dozen randomized trials have shown significant benefit," wrote C.J. Cruich and colleagues, "authors of an analysis published in a recent issue of Clinical Infectious Diseases have raised questions about the efficacy of antimicrobial impregnated CVCs because of perceived defects in the experimental...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.